Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 04 entities : Gilead sciences, inc. save search
Kite's Tecartus® Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation
Published: 2021-06-04 (Crawled : 20:00) - biospace.com/
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 0.47%
H: 1.17%
C: 0.96%
leukemia t-cell designation
Worldwide CAR-T Cell Therapy Industry - Featuring Aleta BioTherapeutics, Atara Biotherapeutics and BioNTech Among Others
Published: 2021-06-04 (Crawled : 16:00) - prnewswire.com
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.28%
H: 0.38%
C: -0.06%
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 1.73%
H: 2.43%
C: -1.58%
PGEN | $1.4 1.45% 1.43% 510K
|
Health Technology
|
| O: 1.07%
H: 3.01%
C: 0.45%
PSTX | $2.15 -0.23% -0.23% 420K
|
Health Technology
|
| O: -1.07%
H: 2.53%
C: 0.84%
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: 2.46%
H: 8.41%
C: 6.91%
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 0.47%
H: 1.17%
C: 0.96%
FATE | News | $4.54 -5.02% -5.29% 4M
|
Health Technology
|
| O: 1.53%
H: 9.81%
C: 6.61%
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: 0.0%
H: 2.74%
C: 0.68%
ANIX | $3.06 1.66% 1.63% 73K
|
Health Technology
|
| O: 1.78%
H: 6.25%
C: 3.0%
therapy car-t iot t-cell
List of Determinations Including Written Request
Published: 2021-06-04 (Crawled : 15:56) - fda.gov
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.79%
H: 0.55%
C: 0.19%
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 0.47%
H: 1.17%
C: 0.96%
Jounce Therapeutics Presents Trial in Progress Posters on the INNATE and SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
Published: 2021-06-04 (Crawled : 13:00) - globenewswire.com
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
|
| O: 0.0%
H: 1.63%
C: -2.14%
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 0.47%
H: 1.17%
C: 0.96%
clinical trials trial
SELECTION study on filgotinib in ulcerative colitis published in The Lancet
Published: 2021-06-04 (Crawled : 12:00) - biospace.com/
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 0.47%
H: 1.17%
C: 0.96%
GLPG | News | $29.47 1.38% 1.36% 120K
|
Health Technology
|
| O: 0.1%
H: 1.07%
C: 0.0%
lancet ulcerative colitis
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.